Dengue vaccines: Are they safe for travelers?

Travel Med Infect Dis. Jul-Aug 2016;14(4):378-83. doi: 10.1016/j.tmaid.2016.06.005. Epub 2016 Jun 22.

Abstract

The four dengue viruses (DENV) circulate among nearly one-half of the world's population in tropical and semitropical countries imposing a huge morbidity burden on travelers. Sanofipasteur has developed a tetravalent live-attenuated vaccine, Dengvaxia, recently approved by the World Health Organization and licensed in four dengue-endemic countries. An additional two dengue vaccines, developed by the National Institute of Allergy and Infectious Diseases (NIAID), USA and Takeda, are entering phase III testing. Dengvaxia is composed of four yellow fever 17D-DENV chimeras, the NIAID vaccine contains three mutagenized DENV and one DENV2/4 chimera while the Takeda vaccine contains an attenuated DENV 2 and three DENV 2-DENV chimeras. Which of these vaccines might be useful in protecting travelers against dengue infections and disease? Dengvaxia requires three doses administered over the course of one year but in addition has safety signals suggesting that susceptible individuals should not be vaccinated. The NIAID vaccine is promising as a travel vaccine as a single dose fully protected susceptible adults against live dengue 2 virus challenge. The protective efficacy and safety of the Takeda vaccine remain to be demonstrated.

Keywords: Antibody dependent enhancement; Arbovirus; Dengue; Efficacy; Vaccine.

MeSH terms

  • Adult
  • Clinical Trials, Phase III as Topic
  • Dengue / immunology
  • Dengue / prevention & control*
  • Dengue Vaccines* / administration & dosage
  • Dengue Vaccines* / adverse effects
  • Dengue Vaccines* / immunology
  • Dengue Virus / genetics
  • Dengue Virus / immunology
  • Humans
  • Immunization Schedule
  • Travel*
  • Vaccination

Substances

  • Dengue Vaccines